Adagene Inc ADR (ADAG)

Jan 29, 2025, 6:14 AM EST - 25 days ago

CD47 Inhibitor Drug Clinical Trials Market Opportunity Outlook 2028, Competitive Analysis of Adagene, ALX, ImmuneOncia, ImmuneOnco, Light Chain Bioscience, Phanes, and Virtuoso,

Jan 21, 2025, 5:00 PM EST - 4 weeks ago

Adagene to Announce Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at ASCO Gastrointestinal Cancers Symposium

Nov 7, 2024, 10:01 AM EST - 3 months ago

Adagene Presents Two Posters with New Insights on Increased Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) and Data Reinforcing Clinical Safety and Efficacy for ADG126 as Monotherapy and in Combination with Anti-PD-1 Therapy at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

Oct 9, 2024, 6:00 AM EDT - 4 months ago

Adagene Announces Upcoming Poster Presentations on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

Sep 16, 2024, 3:01 AM EDT - 5 months ago

Adagene Presents Results at ESMO Congress that Show Best-in-Class Therapeutic Potential for Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) in Combination with KEYTRUDA® (Pembrolizumab) in Advanced/Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)

Jul 12, 2024, 7:00 AM EDT - 8 months ago

Adagene Announces Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at Upcoming European Society for Medical Oncology (ESMO) Congress in September

May 22, 2024, 4:45 PM EDT - 9 months ago

Adagene to Present at Investor Conferences in June

Mar 29, 2024, 9:00 AM EDT - 11 months ago

Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update

Mar 7, 2024, 4:01 PM EST - 1 year ago

Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board

Feb 27, 2024, 8:00 AM EST - 1 year ago

Adagene to Present at the Leerink Partners Global Biopharma Conference 2024

Feb 9, 2024, 6:00 AM EST - 1 year ago

Adagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with KEYTRUDA® (pembrolizumab) to Demonstrate Further Efficacy in Patients with Metastatic Microsatellite-stabl

Jan 16, 2024, 5:01 PM EST - 1 year ago

Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)

Jan 4, 2024, 5:00 AM EST - 1 year ago

Adagene To Present Interim Results of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at ASCO-GI Symposium

Nov 3, 2023, 12:00 PM EDT - 1 year ago

Adagene Presents Data Demonstrating the Best-in-Class Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 at SITC 2023

Oct 12, 2023, 8:00 AM EDT - 1 year ago

Adagene Announces Poster Presentation on Optimal Dose Selection for Masked Anti-CTLA-4 SAFEbody® ADG126 at Upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

Sep 7, 2023, 6:00 AM EDT - 1 year ago

Adagene to Present at Investor and Scientific Conferences in September

Aug 31, 2023, 7:32 AM EDT - 1 year ago

Adagene Reports Six Month Financial Results for 2023 and Provides Corporate Update

May 4, 2023, 9:00 AM EDT - 1 year ago

Adagene Achieves $3 Million Milestone in Collaboration with Exelixis for Successful Nomination of Second SAFEbody® Novel Masked Antibody-Drug Conjugate

Apr 28, 2023, 7:00 AM EDT - 1 year ago

Adagene Announces Updates to its Board of Directors

Apr 18, 2023, 9:17 AM EDT - 2 years ago

Adagene Presents Clinical Data for Anti-CTLA-4 SAFEbody® ADG126 Reinforcing Best-in-Class Safety Profile at Repeat Doses and Showing Early Efficacy Profile in Advanced/Metastatic Solid Tumors

Mar 28, 2023, 4:30 PM EDT - 2 years ago

Adagene Reports Full Year 2022 Financial Results and Provides Corporate Update

Mar 14, 2023, 6:00 PM EDT - 2 years ago

Adagene Announces Poster Presentations on Anti-CTLA-4 SAFEbody®, ADG126, at Upcoming American Association for Cancer Research (AACR) Annual Meeting in April

Mar 5, 2023, 7:39 PM EST - 2 years ago

Adagene Appoints Professor Aurélien Marabelle to Scientific and Strategic Advisory Board

Jan 9, 2023, 7:00 AM EST - 2 years ago

Adagene Announces Interim Data Demonstrating Safety and Confirmed Clinical Responses of Anti-CTLA-4 SAFEbody® ADG126 up to 10 mg/kg with Repeat Cycles in Combination with Anti-PD-1 Therapy from Dose Escalation Portion of Phase 1b/2 Trial

Jan 5, 2023, 4:01 PM EST - 2 years ago

Adagene to Present at the Biotech Showcase™ 2023 in San Francisco on January 9

Dec 16, 2022, 6:30 AM EST - 2 years ago

Adagene Announces Clinical Trial Collaboration to Evaluate Anti-CTLA-4 SAFEbody® ADG126 in Combination with Roche's Standard-of-Care for First-Line Advanced Liver Cancer

Nov 21, 2022, 4:05 PM EST - 2 years ago

Adagene Appoints Cuong Do to Board of Directors and Audit Committee

Nov 10, 2022, 9:05 AM EST - 2 years ago

Adagene Announces Clinical Data at SITC 2022 on Anti-CTLA-4 NEObody™, ADG116, Showing Differentiated Safety and Anti-tumor Activity in Heavily Pre-treated Patients with Difficult-to-Treat Tumors

Oct 11, 2022, 4:03 PM EDT - 2 years ago

Adagene Announces Poster Presentations on Anti-CTLA-4 NEObody™, ADG116, at Upcoming Society for Immunotherapy of Cancer's (SITC) Annual Meeting in November

Sep 10, 2022, 4:13 AM EDT - 2 years ago

Adagene Presents Interim Monotherapy Data at ESMO 2022 Showing Compelling Safety, Anti-Tumor Activity and Pharmacokinetics of Masked, Anti-CTLA-4 SAFEbody® ADG126 in Patients with Advanced Tumors

Aug 30, 2022, 5:25 PM EDT - 2 years ago

Adagene Reports Financial Results for the Six Months Ended June 30, 2022 and Provides Corporate Updates

Jun 29, 2022, 4:05 PM EDT - 2 years ago

Adagene Announces Authorization of Share Repurchase Program up to US$10 Million

May 26, 2022, 5:00 PM EDT - 2 years ago

Adagene Announces Publication at ASCO of Interim Monotherapy Dose Escalation Data Showing Compelling Safety Profile of Anti-CTLA-4 SAFEbody® ADG126, with Repeat Dosing Across Dose Levels

May 12, 2022, 7:00 AM EDT - 3 years ago

Adagene to Participate in Investor Conferences in May and June

Apr 8, 2022, 1:09 PM EDT - 3 years ago

Adagene Presents Data Demonstrating First and Best-in-Class Potential for Differentiated Preclinical Antibody Candidates at American Association for Cancer Research (AACR) Annual Meeting 2022

Mar 31, 2022, 8:30 AM EDT - 3 years ago

Adagene Reports Full Year 2021 Financial Results and Provides Corporate Update

Mar 16, 2022, 10:07 AM EDT - 3 years ago

Adagene Shares Pop After FDA Clears Phase 1b/2 Trial For ADG126/Keytruda Combo Therapy In Solid Tumors

Mar 16, 2022, 7:00 AM EDT - 3 years ago

Adagene Announces FDA Clearance to Proceed with Phase 1b/2 Trial of Anti-CTLA-4 ADG126 SAFEbody® in Combination Therapy With Anti-PD-1 Antibody Pembrolizumab

Mar 10, 2022, 5:30 PM EST - 3 years ago

Investors Hoping for News at Cancer Meeting That Will Boost Share Prices

AMGN LLY

Mar 8, 2022, 5:28 PM EST - 3 years ago

Adagene Announces Four Poster Presentations on Robust Preclinical Pipeline of Antibody-Based Therapeutics at Upcoming American Association for Cancer Research (AACR) Annual Meeting

Mar 2, 2022, 9:55 AM EST - 3 years ago

Sanofi Taps Adagene's 'Masking' Tech In Over $2.5B Immuno-Oncology Pact

SNY

Mar 2, 2022, 8:22 AM EST - 3 years ago

Sanofi to pay up to $2.5 billion in deal with Adagene

SNY

Mar 2, 2022, 6:00 AM EST - 3 years ago

Adagene Announces SAFEbody® Multi-Target Collaboration with Sanofi for Novel Masked Immuno-Oncology Antibody Candidates

Feb 8, 2022, 7:00 AM EST - 3 years ago

Adagene to Participate in the SVB Leerink 11th Annual Global Healthcare Conference

Feb 2, 2022, 4:05 PM EST - 3 years ago

Adagene Announces Board and Management Appointments to Support Pipeline Growth

Jan 27, 2022, 7:00 AM EST - 3 years ago

Adagene Announces First Patient Dosed with Novel, Proprietary Combination of Anti-CD137 Agonist, ADG106, and Anti-CTLA-4 Monoclonal Antibody, ADG116

Jan 19, 2022, 7:00 AM EST - 3 years ago

Adagene Expands Scientific and Strategic Advisory Board with Appointment of David Gandara, M.D.

Jan 13, 2022, 4:00 AM EST - 3 years ago

Adagene Announces First Patients with Advanced Non-Small Cell Lung Cancer Dosed in Phase 1b/2 Clinical Trial of ADG106 in Combination with Nivolumab in Singapore

Dec 22, 2021, 4:05 PM EST - 3 years ago

Adagene Achieves Key Milestone in Collaboration with Exelixis for SAFEbody® Novel Masked Antibody-Drug Conjugate Candidates

Dec 13, 2021, 10:23 AM EST - 3 years ago

Adagene Presents Preclinical Data Showcasing Best-in-Class Profiles for ADG153, an Anti-CD47 SAFEbody® and ADG152, a CD20xCD3 Bispecific T-cell Engager POWERbody™